Stock Analysis, Dividends, Split History

HLNE / Hamilton Lane INC financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,109.61
Enterprise Value ($M)1,221.03
Book Value ($M)83.53
Book Value / Share3.26
Price / Book14.26
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 25,700,068
Common Shares Outstanding 23,131,428
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.65
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Incentive Fee Revenue Carried Interest Unrecorded Estimate303,766,000.00
Net Income106.30
Cash Flow Statement (mra) ($M)
Cash From Operations96.69
Cash from Investing-21.77
Cash from Financing-21.77
Identifiers and Descriptors
Central Index Key (CIK)1433642
Industry Groups

Split History

Stock splits are used by Hamilton Lane INC to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

LAZ vs. HLNE: Which Stock Should Value Investors Buy Now?

2018-08-11 zacks
Investors with an interest in Financial - Investment Management stocks have likely encountered both Lazard Ltd (LAZ - Free Report) and Hamilton Lane (HLNE - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. (43-0)

Hamilton Lane Inc (HLNE) CEO Mario Giannini on Q1 2019 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Hamilton Lane Inc (NASDAQ:HLNE) Q1 2019 Results Earnings Conference Call August 7, 2018 11:00 AM ET (5-0)

Hamilton Lane (HLNE) Q1 Earnings Match Estimates

2018-08-07 zacks
Hamilton Lane (HLNE - Free Report) just came out with quarterly earnings of $0.38 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. (1-0)

Why the Earnings Surprise Streak Could Continue for Hamilton Lane (HLNE)

2018-07-26 zacks
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Hamilton Lane (HLNE - Free Report) , which belongs to the Zacks Financial - Investment Management industry. (1-0)

Will High Equity Markets Drive Franklin (BEN) Q3 Earnings?

2018-07-26 zacks
Franklin Resources, Inc. (BEN - Free Report) is scheduled to report third-quarter fiscal 2018 results, before the opening bell on Jul 27. The company’s results are projected to reflect a year-over-year rise in earnings and decline in revenues. In the last reported quarter, Franklin outpaced the Zacks Consensus Estimate, driven by rise in revenues. Nevertheless, elevated operating expenses remained a headwind. (3-0)

CUSIP: 407497106